The initial POC results, presented April 26, 2025 at the Annual ELITE PED-GI Congress, show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to ...

The Food and Drug Administration Agency (FDA) has updated the regulatory status of Marie®, Leo Cancer Care's upright particle ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical GuidanceClick here to access replay of company's April 30, 2025 investor webcast SAN FRAN ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.

The annual event for the military medical research and development community had another successful year as a record 800 ...